AI in medcomms raises significant ethical concerns around accuracy, accountability, transparency, and scientific integrity. Medical communications directly influences how healthcare professionals, patients, and payers understand disease and treatment — so the stakes of getting content wrong are considerably higher than in most other industries. The questions below work through the most pressing issues facing medcomms teams, agencies, and pharmaceutical companies as AI becomes a more prominent part of the content production process in 2026.
How is AI currently being used in medical communications?
AI is being used across the medcomms workflow to accelerate content production, analyse scientific literature, support regulatory submission writing, personalise educational materials, and generate first drafts of everything from congress abstracts to patient-facing disease awareness content. Its role ranges from assistive to generative, depending on the team and the task.
In practical terms, large language models are helping medical writers scan and summarise clinical data at speed, reducing the time it takes to move from data lock to publication-ready manuscript. AI tools are also being applied to medical information response generation, MSL briefing documents, and the adaptation of global content for local markets. On the commercial side, some teams are using AI to develop payer value stories and market access dossiers, drawing on structured datasets to identify and frame evidence.
The appeal is clear: volume, speed, and cost. But applying AI in medcomms is rarely straightforward. The scientific and regulatory expectations that govern pharmaceutical communications do not flex to accommodate the limitations of AI, and that tension sits at the heart of every ethical question the industry is now working through.
What are the biggest ethical risks of AI-generated medical content?
The biggest ethical risks are hallucination, bias amplification, and the erosion of scientific rigour. AI systems can produce plausible-sounding but factually incorrect statements, misattribute clinical data, or reflect biases embedded in their training data — all without flagging any of this to the user.
Hallucination is the most immediately dangerous risk. Unlike a human medical writer who knows when they are uncertain, a generative AI model will produce confident, well-structured text even when the underlying claim is fabricated or the citation does not exist. In a field where a single inaccurate efficacy statement can mislead a prescriber or trigger a regulatory complaint, this is not a minor inconvenience.
Bias presents a subtler but equally serious problem. If the data used to train an AI model overrepresents certain patient populations, geographies, or therapeutic approaches, the content it generates will reflect those imbalances. Medical communications that systematically underrepresents women, older patients, or non-Western populations in how it frames evidence does real harm to clinical decision-making.
There is also the risk of content homogenisation. When multiple agencies and companies rely on the same AI tools, the strategic and scientific differentiation that good medcomms depends on begins to erode. Distinctive scientific narratives get flattened into generic outputs that serve no one’s interests particularly well.
Who is responsible when AI produces inaccurate medcomms content?
Responsibility sits with the humans and organisations that commissioned, reviewed, and approved the content. AI is a tool, not an author. The pharmaceutical company, the agency, and the named medical writer or scientific director who signed off on the content bear the same accountability they would for any other piece of regulated communications.
This matters because it closes what some teams mistakenly treat as a liability loophole. Attributing an error to the AI does not absolve the organisation. Under the ABPI Code of Practice in the UK, the EFPIA guidelines in Europe, and equivalent frameworks in the US, the sponsoring company remains responsible for the accuracy and balance of all promotional and non-promotional materials, regardless of how they were produced.
The practical implication is that AI cannot replace the medical, legal, and regulatory review process. It can sit upstream of that process, but human review must be substantive, not perfunctory. Rubber-stamping AI output without genuine scientific scrutiny is both a regulatory risk and an ethical failure.
There is also a question of professional accountability. Medical writers who use AI without disclosing it and without applying appropriate critical review are operating outside the standards set by bodies such as the International Society for Medical Publication Professionals. The tool changes; the professional obligation does not.
How does AI in medcomms affect transparency and disclosure obligations?
AI use in medcomms creates new transparency obligations that the industry is still working to standardise. At minimum, teams should be disclosing AI involvement in content creation to their clients, and in some publication contexts, to journals and congress organisers. Failure to disclose is increasingly treated as a breach of good publication practice.
Several major medical journals now require authors to declare whether AI tools were used in manuscript preparation, and most specify that AI cannot be listed as an author because it cannot take responsibility for the work. The International Committee of Medical Journal Editors has been clear on this point, and congress abstract submission guidelines are moving in the same direction.
For promotional and non-promotional pharmaceutical content, disclosure requirements are less formally codified but ethically no less important. Healthcare professionals receiving AI-generated medical information letters, educational content, or digital learning modules have a reasonable expectation that the content has been produced and verified by qualified humans. Where AI has played a significant generative role, that should be transparent.
The broader issue is one of trust. Medical communications depends on the credibility of the source. Undisclosed AI involvement, if discovered, damages that credibility in ways that are difficult to recover from — both for the agency and for the pharmaceutical company whose name is on the material.
Can AI uphold the scientific integrity standards medcomms requires?
AI alone cannot uphold the scientific integrity standards that medcomms requires. It can support scientific communication, but it cannot replace the expert judgement, contextual understanding, and ethical reasoning that rigorous medical writing demands. Scientific integrity in this field is not just about accuracy; it is about balance, context, and the responsible representation of uncertainty.
A well-trained medical writer understands not just what a clinical trial found, but what the study design means for how those findings should be interpreted, what the confidence intervals imply about effect size, and how the results sit within the broader evidence base. They understand when a subgroup analysis is hypothesis-generating rather than conclusive, and they know how to communicate that distinction clearly without undermining a legitimate scientific story.
AI does not understand any of this in the way a human expert does. It pattern-matches on language. That is enormously useful for drafting, summarising, and structuring, but it is not sufficient for the scientific judgement that separates compliant, credible medcomms from content that misrepresents the evidence, even subtly.
AI can raise the floor of medcomms production efficiency without raising the ceiling of scientific quality. That ceiling still depends entirely on the expertise and integrity of the people involved.
What safeguards should medcomms teams put in place when using AI?
Medcomms teams using AI should implement a structured governance framework that covers tool selection, disclosure protocols, review requirements, and quality assurance. The goal is to capture AI’s efficiency benefits without compromising the scientific accuracy and regulatory compliance that the work demands.
The most important safeguards include:
- Mandatory human review by a qualified medical writer or scientific director for all AI-generated content before it enters the approval process. This review must be substantive, not superficial.
- Source verification at the claim level: every factual statement generated by AI should be checked against the original source material, not accepted on the basis of the AI’s citation.
- Clear internal disclosure policies that define when and how AI use must be declared to clients, journals, congress organisers, and regulatory reviewers.
- Defined scope of use: specifying which tasks AI is permitted to support (drafting, summarising, reformatting) and which require human authorship from the outset (clinical data interpretation, benefit-risk characterisation, regulatory submission narratives).
- Training for all team members on the limitations of AI tools, including hallucination risk, bias, and the difference between AI-assisted drafting and AI-generated content.
- Regular auditing of AI-assisted outputs against quality benchmarks to identify patterns of error or inconsistency before they reach clients or regulators.
Governance frameworks should also account for the specific regulatory environment of each market. What is acceptable practice in the UK under ABPI guidance may differ from requirements in the US under FDA oversight or in Europe under EMA and EFPIA frameworks. A one-size approach to AI policy is unlikely to hold across an international medcomms programme.
How Wizzard approaches responsible AI in medical communications
Our starting point is that AI should sharpen human expertise, not replace it. Working across pharmaceutical, healthcare, and wellbeing sectors, we integrate AI tools where they genuinely add value — while maintaining the scientific rigour, regulatory compliance, and creative quality that clients rightly expect.
- All medcomms content is produced and reviewed by experienced in-house medical writers and scientific strategists
- AI is used to support drafting and research efficiency, never to bypass the expert review process
- Disclosure and governance standards are applied consistently across client programmes
- Scientific integrity is treated as a non-negotiable, regardless of which tools are used in production
- Creative ambition and scientific credibility are held in balance, reflecting Wizzard’s “science seen creatively” positioning
If your organisation is working out how to use AI responsibly within a medical communications programme, talk to our medcomms team about how a structured, expert-led approach can protect both quality and compliance.